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ABSTRACT
Jennifer Harlow: Distraction and the Provision of Risk and Benefit Information
in Prescription Drug Television Advertising
(under the direction of Heidi Hennink-Kaminski, Ph.D.)
Direct-to-consumer (DTC) advertising of prescription drugs is one of the fastest
growing and most controversial forms of consumer marketing. One criticism of DTC
advertising is that it misleads consumers by providing them with benefit information
while distracting them from information about drug risks. Despite this, there has been
very little scholarly research about the prevalence of distracting elements during the
presentation of risk and benefit information in DTC television advertising. This thesis
was designed to fill this gap in literature and its purpose is two-fold. First, the thesis
proposes a definition of distraction in television advertising, drawing from the capacity
model of attention and the related conceptual frameworks of information load and
information relevance. Second, it reports the results of a content analysis of 58 DTC
television advertisements. Findings suggest that some forms of distraction are more
prevalent during risk information than during claims about drug benefits. Given the
pervasiveness of DTC advertising on television, this study has clear implications for
consumers, public policy makers, health care providers, and pharmaceutical marketers.
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CHAPTER ONE
Introduction
Direct-to-consumer (DTC) advertising of prescription drugs is one of the fastest
growing forms of consumer marketing. Since its controversial beginning in the 1980s,
prescription medicine has become the second largest advertising category in the U.S. market,
only led by automotive (Nielsen, 2009). In 2008 alone, American pharmaceutical companies
accounted for $5.1 billion in advertising expenditures. According to IMS Health (2004), a
for-profit source for pharmaceutical marketing intelligence, promotional spending has
yielded increased sales for at least 49 brand-name drugs. A Kaiser Family Foundation
(2003) study of return on investment in DTC advertising found that at least 90% of the
brands demonstrated positive returns with an average yield of an additional $4.20 in sales for
every dollar spent. The growth in prescription drug advertising has inspired great interest in
this category among marketing practitioners, scholars and the medical community.
While annual expenditures keep going up, the debate over the merits and
effectiveness of DTC advertising also escalates. Proponents of DTC advertising contend that
the explosion in prescription drug advertising is fueling a trend toward better-informed
consumers and emphasize its potential to educate consumers and encourage beneficial
dialogue between physicians and patients (Kravitz & Bell, 2007). Prior research
demonstrates that consumers utilize information in DTC ads in decisions about their health
care (Desphande, Menon, Perri & Zinkhan, 2004; Huh, DeLorme, & Reid, 2004) and that it
2can increase consumers’ awareness of medical conditions and treatments (Perri & Dickson,
1988; Perri & Nelson, 1987). These findings were echoed by a Food and Drug
Administration (FDA) report (2003) that concluded that DTC ads can serve positive public
health functions such as increasing public awareness of treatable conditions and prompting
consumers to seek appropriate treatment from their doctors.
Critics of DTC advertising argue that prescription drugs should not be promoted in
the same manner as other consumer products. Currently, the United States and New Zealand
are the only two countries that permit DTC advertising (Roth, 2003). Opponents have raised
concerns that the ads contribute to over-diagnosis (Mintzes, 2003), patient anxiety, disruption
of the patient-physician relationship, rising health care costs (Kravitz & Bell, 2007), and the
medicalization of conditions that were previously regarded as ordinary, non-medical aspects
of the human condition (Conrad, 2005).
In the United States, the FDA regulates the content of DTC advertisements,
specifying that such ads cannot be false or misleading and requires that DTC advertisers give
a “fair balance” of information about benefits and risks. These risks may include side
effects, allergic reactions, or contraindications. A growing body of literature is largely
critical of DTC advertisers, arguing that DTC ads mislead consumers by providing them with
benefit information while failing to comply with the FDA’s fair balance requirement, which
requires that "[T]he presentation of true information relating to side effects and
contraindications is comparable in depth and detail with the claims for effectiveness or
safety" (FDA, 1997, p.2).
The bulk of DTC advertising dollars have been spent on television, accounting for
62% of total DTC media spending in 2008 (Neilsen, 2009). Television ads create special fair
3balance compliance challenges for marketers of prescription drugs and policy makers
because of the interplay of two different sensory modalities (audio and visual) used to present
risk and benefit information. Broadcast prescription drug ads are required to present major
product risks in the audio portion of the ads. In a new Draft Guidance proposed in May
2009, FDA regulators recommend that risks should be “presented in clear, understandable
language without distraction” (p.20). The draft guidelines do not offer a definition of
distraction per se, but suggest that message elements such as background visuals and on-
screen text can interfere with consumer comprehension by distracting attention away from
the information being presented.
Despite the fact that the FDA has specifically recognized distraction in DTC
advertising as a potential concern with implications for marketers and consumer safety, there
has been very little scholarly research about the prevalence of distracting elements during the
presentation of risk and benefit information in DTC broadcast ads. The purpose of this
study is two-fold: 1) to propose an operational definition of distraction in television
advertisements to help guide policy makers and pharmaceutical marketers and 2) to assess
the prevalence of distracting elements in DTC prescription drug television advertisements.
The following section describes the FDA’s existing authority to regulate DTC
advertising and current policy issues related to distraction. Prior research on DTC television
advertising is then discussed, focusing specifically on studies that have examined features of
DTC ads with implications for fair balance of risk and benefit information. The paper then
provides a definition of distraction in DTC advertising, drawing from the capacity model of
attention (Kahneman, 1973) and related conceptual frameworks of information load and
information relevance.
CHAPTER TWO
Background
Regulation of DTC Advertising
A 2005 Congressional Report defined direct-to-consumer (DTC) prescription drug
advertising as “any promotion designed by pharmaceutical companies to communicate to the
public about prescription drugs through the lay media” (Vogt, 2005, p.1). DTC ads usually
fall into one of three categories:
1. Product-claim ads contain the brand name of a drug and claims about the
product’s therapeutic use for a particular health condition;
2. Help-seeking ads contain information about the particular health condition
that the drug treats and encourage consumers to talk to their doctor about the
condition, but they do not contain the drug’s brand name nor do they mention
any claims about a drug’s uses;
3. Reminder ads call attention to a drug’s brand name but do not mention any
particular condition or make claims about the product’s uses.
The Federal Food, Drug and Cosmetic Act (FFDCA) provides the statutory
requirements for marketing a prescription drug in the United States.1 When the FFDCA was
enacted in 1938, most prescription drug promotion was in the form of written material
directed at physicians. In 1962, Congress added section 502(n) to the Act, giving the FDA
jurisdiction over drug labeling and advertising. The section included several important
requirements for the marketing of new drugs. New drugs must be proven safe and effective
1 Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301 – 399 (1938).
5before they can be sold in the United States, and any claims about the product’s uses or
effectiveness must be substantiated by adequate clinical testing. This requirement that all
claims must be substantiated is the legal framework for the FDA’s jurisdiction over product-
claim advertising.
In 1969, the FDA issued regulations for product-claim advertising.2 Product-claim ads
must have four characteristics:
1. They cannot be false or misleading;
2. They must present a “fair balance” of claims about the drug’s therapeutic uses and
effectiveness and the drug’s risks
3. They must contain “facts” that are “material” to the drug’s use;
4. They must include all risks from the drug’s approved labeling in a “brief
summary.”
Prior to 1999, the FDA did not distinguish between print and broadcast ads.
However, the requirement that product-claim ads had to provide a “brief summary” that
included all risks from a drug’s approved labeling made it nearly impossible for advertisers
to use broadcast ads. The product label contains information about all risks including side
effects, contraindications, and precautions. Because broadcast advertisements are often only
30- or 60- seconds long, it was difficult for advertisers to include this type of detailed
information.
In August 1999, the FDA issued its Guidance for Industry: Consumer-Directed
Broadcast Advertisements that made it much easier for pharmaceutical companies to
advertise prescription drugs on television. The 1999 guidance represented “the Agency's
current thinking [at the time] on procedures to fulfill the requirements for disclosure of
2 21 C.F.R. § 202.1
6product information,” (FDA, 1999, p.1). Guidances are not binding law, but are designed to
help industry members comply with current regulation. The FDA’s 1999 guidance paved the
way for drug companies to use broadcast media for product-claim ads without a brief
summary, provided that they included the advertised drug’s most important risks, called a
“major statement” (FDA, 1999, p.2). The major statement is required to be in the audio
portion of the advertisement, but can be in the video portion as well. The regulations also
require that broadcast advertisements must “present a fair balance between information about
effectiveness and information about risk” (FDA, 1999, p.2).
In assessing fair balance, the FDA not only looks at the number and quality of
specific benefit and risk statements, but also at the “net impression” of all the elements
communicated in the message as a whole (FDA, 2009, p. 4). In a 2009 draft guidance, the
FDA responded to requests for specific guidance about how it evaluates adequate risk
information in promotional messages (FDA, 2009). The draft guidance suggests that in order
to ensure comparable benefit and risk presentations, manufacturers should consider not only
the time devoted to benefits and risks and the number of statements about each, but also the
comprehensibility of the language used and the type of information provided. The 2009 draft
guidance specifically warns against “the use of audio or visual components that enhance or
distract from the presentation of risk or benefit information” (FDA, 2009, p. 11).
If an ad is deemed to be violative, the FDA’s Division of Drug, Marketing,
Advertising and Communications (DDMAC) team can issue a “warning letter” to the
pharmaceutical company asking that the ad be stopped. The 2009 draft guidance followed
warning letters sent from the FDA to Novartis and Bayer HealthCare Pharmaceuticals that
cite distracting background visuals during the presentation of risk information. The FDA
7(2003a) warned Novartis regarding its Lamisil commercial that “the distracting animated
visuals and sound effects hamper the communication of the risk information. In addition,
SUPERs [text superimposed on-screen] appear on the bottom of the screen during this busy
activity [of the commercial animation], thus further distracting from this important
information” (p.3). Similarly, a warning letter sent to Bayer HealthCare Pharmaceuticals
regarding an ad for the Premenstrual Dysphoric Disorder (PMDD) drug YAZ said that the
audio communication of serious risk disclosures during the “major statement” is minimized
by distracting visuals, numerous scene changes, and other competing modalities such as
background music, which combined to interfere with the presentation of the risk information
(FDA, 2009a). Schering-Plough Corp was ordered to discontinue an ad for allergy drug
Nasonex after a congressional hearing determined that background visuals in the ad had the
potential to distract consumers from side effect information (FDA, 2008). The ad featured a
bee that flew around during a description of side effects but simply hovered while benefits
were being explained.
The heightened concern about distraction in DTC advertising has triggered self-
regulation. Drug companies and medical device manufacturers have responded by adopting
voluntary advertising principles for presenting risk information in a manner free from
distraction. The most recent revision of the Pharmaceutical Research and Manufacturers of
America (PhRMA)’s voluntary Guiding Principles (2008) says that DTC advertising should
be designed to achieve a balanced presentation of both the benefits and risks of the advertised
medicine “in a clear, conspicuous and neutral manner, and without distraction from the
content” (p.7).
8Further demonstrating its interest in the issue of distraction in DTC advertising, the
FDA has initiated a study on the impact of distracting visuals on viewer comprehension of
the risks and benefits of advertised drugs (2008). In its proposed study, Experimental
Evaluation of the Impact of Distraction on Consumer Understanding of Risk and Benefit
Information in DTC Prescription Drug Ads, the FDA’s DDMAC project team suggests that if
visuals in a broadcast ad distract the audience from carefully considering the audio
presentation of a drug’s risks, the ad will not convey an accurate net impression of the
benefits and risks of the advertised product.
The FDA’s proposed study will examine the role of textual elements and background
visuals in the processing of risk information. Advertisers often place superimposed text
(“SUPERS”) onto the screen to clarify spoken information or to provide extra information
that is not included in the audio. For example, during the required description of product’s
most serious and frequent risks in the ad’s audio, information such as adequate provision
statements (“See our ad in…”) and limits to indication statements may appear on screen. The
FDA suggests that this text potentially has the power to distract viewers from the more
important audio information if it is inconsistent with the audio portion. The FDA study will
also investigate the distracting effect of visuals with a positive tone during the audio
presentation of risk information.
While the purpose of the FDA study is to investigate the effect of distracting creative
elements on consumer comprehension of risk information, there is little scholarly research to
address the extent to which distraction is actually prevalent in today’s DTC advertising
landscape. Consequently, this thesis is designed to fill this gap in literature by investigating
9the prevalence of distracting message elements in product-claim advertising in order to
inform future DTC advertising policy and pharmaceutical marketing practices.
CHAPTER THREE
Literature Review
A Definition of Distraction
In order for DTC advertising to educate consumers, messages must provide
information they need to make informed decisions. For DTC advertising to be persuasive, it
must result in positive attitudes and safe use. There is growing concern about the extent to
which DTC advertising is both persuasive and educational about drug risks and benefits.
A key feature of product-specific DTC drug advertising is the balance of benefit and
risk information presented to consumers. A number of studies have concluded that
consumers comprehend benefit information better than risk information in DTC ads
(Abernathy & Adams-Price, 2006; Day, 2005; Glinnert & Schommer, 2005). Television ads
create special fair balance compliance challenges for three reasons: the interplay of two
different sensory modalities (audio and visual), the amount of information communicated in
a relatively short period of time, and the incongruent nature of the two types of information
presented (possible positive and negative outcomes of using the product). These
characteristics of DTC television ads create opportunities for distraction of consumers from
information in the message.
Distraction in DTC television advertising is not specifically defined in FDA
regulations or in industry self-regulation. Previous research in psychology and mass
communication, however, suggests several circumstances in which distraction from
11
information in advertisements is likely to occur. In cognitive psychology, distraction is
defined simply as divided attention (Hunt & Ellis, 2004). Capacity models of attention
(Kahneman, 1973) assume that our psychological resources are finite; that is, every person,
regardless of expertise, only has a certain amount of cognitive capacity to devote to various
mental tasks. Different tasks require different amounts of this capacity, and the number of
activities that can be done simultaneously is determined by the capacity that each requires.
Attention is the process of allocating cognitive resources to various mental tasks. Attention is
important in determining which mental tasks are accomplished and how well they are
performed. Thus, distracting, or dividing viewers’ attention from information in a message
can affect how well viewers comprehend that information. Previous research suggests that
both information load and the relevance of information presented in one channel to the other
have the potential to distract consumers.
Distraction as information load. Information load refers to “the variety of stimuli (in
type and number) to which the receiver must attend” (Jacoby, 1977, p. 569). Research on
consumer information processing (Bettman, 1975; Jacoby, Speller, and Kohn, 1974) suggests
that information overload, or too much information, may reduce subjects’ attention and
comprehension. Experimental studies in consumer psychology research have demonstrated a
number of television advertising elements that can contribute to information load and divided
attention: music (Hahn and Huang, 1999), presentation rate (Wingfield, Lindfield &
Goodglass, 2000), and animation (Hong, Thong, & Tam, 2004).
Mass communication researchers have conceptualized the two types of distraction
inherent in television advertising as visual distraction and audio distraction (See Tiege, 1975;
Festinger & Macoby, 1964). In terms of audio distraction, experimental studies have
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demonstrated that both music and the rate of speech can affect information load. The
presence of music in advertising messages can affect message processing, and both the tempo
and familiarity of the music can moderate these effects. Background music in TV
advertising is information offered to viewers in addition to the main message. Fast tempo
music requires more processing resources than slower tempo music (Hahn & Hwang, 1999).
While the presence of any music increases information load, familiar music can actually
facilitate message processing because it attracts viewers’ attention to the message.
Conversely, unfamiliar music makes message processing more difficult because it distracts
attention away from the message.
The rate at which spoken information in an advertisement is presented can also affect
information load. Successful comprehension of spoken information routinely occurs for
speech presented at an average rate of 140 to 180 words per minute (Wingfield, Lindfiled,
and Goodglass, 2000). A presentation rate of greater than 180 wpm is considered insufficient
for successful comprehension of speech communication.
The FDA recognizes the impact of audio information load elements on the
distraction potential of DTC television advertisements. The 2009 guidance notes several
audio factors that the FDA will consider when evaluating distraction in television ads
including verbal pace, volume, and the presence of background music during the presentation
of both benefit and risks (FDA, 2009).
In terms of visual distraction, both the presence and speed of animation on-screen can
distract consumers away from other audio and visual elements of the message (Hong, Thong,
& Tam, 2004). On-screen animation attracts viewers’ attention and distracts it away from the
audio portion, and faster animation is more distracting than slower animation. The FDA also
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recognizes the impact of visual information load elements on the distraction potential of DTC
commercials. The 2009 guidance (FDA, 2009) says that graphics such as on-screen text,
busy scenes, frequent scene changes and moving camera angles can “misleadingly minimize
the risks of the product being promoted by detracting from the audience’s comprehension of
the risk presentation” (p. 20).
Based on this literature review, Table 1 summarizes the operational definition of
distracting audio and visual elements that can contribute to information load.
Table 1
Information Load Elements
Channel Message Elements
Audio Presence of music
Music familiarity
Music tempo
Other sounds (besides music)
Speech presentation rate
Visual Presence of animation
Number of superimposed words
Busy scenes (number of models)
Number of scene changes
Number of camera-angle changes
Distraction as irrelevant stimulation. Television is a two-channel communication
medium involving two sensory modalities, audio and visual. In mass communication
literature, visual information is considered irrelevant to audio information when it is not a
“matching representation of information across communication channels” (Baron, Baron, &
Miller, 1973, p. 310). In studies of the effects of distraction on persuasion, distraction is
often conceptualized as the presentation of stimulation in one channel that is irrelevant to
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information in the other channel (See Tiege, 1975; Festinger & Macoby, 1964). To the
extent that visual elements such as superimposed text or background visuals are irrelevant to
the information being concurrently presented in the audio channel, viewers are distracted
from the audio channel and to the video channel. Persuasion studies have demonstrated that
compelling emotional appeals such as humor (Strick, van Baaren, Holland, & van
Knippenberg, 2009) and sex (Reichert, Heckler, & Jackson, 2001), when irrelevant to the
context of the information being provided in the ad, can distract viewers from carefully
considering the information.
In scholarly literature, the term “irrelevant” is used synonymously with the terms
“discrepant” (Tiedge, 1975) and “incongruous” (Romer, 1979) to describe concurrently
presented information in advertising. While scholarly literature uses the term “irrelevant”
stimulation to describe distracting content, the FDA uses the terms “competing” and
“inconsistent” (2008, p.3). In the 2009 guidance, the FDA refers to irrelevant visual
elements during the audio presentation of risk information as “competing, compelling visual
information” (p.3).
To operationalize competing, compelling visuals in its current experimental
evaluation of the impact of distraction in DTC television advertisements, the FDA
incorporates two types of visual elements, superimposed text and background visuals. That
study has three independent variables: visual consistency with audio risks (VCAR), tonal
consistency with audio risks (TCAR) and the presence and consistency of superimposed text
(SUPERS). The FDA defines VCAR as visual information that either reinforces the
product’s risks being presented in the audio channel (consistent conditions) or reinforces the
product’s benefits (inconsistent condition) (2008). The experimental conditions will examine
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the effects of different types of visual information such as text, background visuals and visual
demonstrations. Reinforcing text is defined as a verbatim repetition of the audio risk;
“competing” text will include contextual information for understanding usage and will not
contain risk or benefit information. In inconsistent conditions, participants will see a visual
demonstration of the product’s benefits.3 The degree or magnitude of consistency or
inconsistency (very consistent, somewhat consistent, neutral, somewhat inconsistent, and
very inconsistent) will be manipulated by the number of statements interspersed with images
of the drug logo. The brand logo is considered a “neutral” image and in neutral conditions,
the brand logo will be the only thing on screen during the entire risk presentation.
The FDA defines tonal consistency with audio risks as scenes that show patients
“living their lives” (FDA, 2008, p. 29), such as socializing with family and friends and
enjoying recreational activities. While the FDA notes that it would be unrealistic for DTC
advertisers to show visual images of patients experiencing side effects, the agency
hypothesizes that visuals that are positive in tone will impede comprehension of audio risk
information more than neutral images. Moreover, the FDA suggests that images evoking a
mildly positive tone will hinder comprehension less than those that are strongly positive.
Drawing from the literature review, Table 2 summarizes the ways in which the two
types of visual elements may be irrelevant to the audio presentation of risk and benefit
information.
3 The DTC ad being manipulated for the experimental treatment is for a blood pressure medicine. In the
inconsistent conditions, participants will see blood pressure numbers decreasing from a high, dangerous number
to an ideal number within a normal range.
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Table 2:
Irrelevant Visual Elements by Commercial Segment
Commercial Segment Type of Irrelevant
Visual Element
Description
Risk Superimposed text Audio statement of drug risks
while superimposed text
presents information
irrelevant to drug risks
Background visuals Audio statement of drug risks
while background visuals
depict information irrelevant
to drug risks
Benefit Superimposed text Audio statement of drug
benefits while superimposed
text presents information
irrelevant to drug benefits
Background visuals Audio statement of drug
benefits while background
visuals depict information
irrelevant to drug benefits
When examined as information load and irrelevant visual elements, distraction in
DTC advertising can influence processing of risk- and benefit- information and consumers’
net impression of the risks and benefits of the advertised drug by drawing cognitive resources
away from some information and to other information.
Distraction as defined in prior content analyses of DTC advertising. Only three
content analyses to date have examined DTC television advertising (Frosch, Kruger, Hornik,
Crohnolm, & Barg, 2007; Kaphingst, Dejong, Rudd, & Daltroy, 2004; Macias, Pashupati,
and Lewis, 2007). Of those, two were specifically designed to examine features of DTC
17
television ads that might interfere with consumer comprehension of the risk information
required in product-claim ads. While they did not specifically address the concept of
distraction, both studies examined elements of advertisements that can increase information
load and irrelevant visual stimulation during the audio presentation of risk information.
Macias, Pashupati, and Lewis (2007) examined in what format risk information was
presented and what proportion of total commercial time is devoted to risk information. The
television advertisements they analyzed were broadcast during a seven-day period in July
2003 on four major television network stations (ABC, CBS, FOX, NBC) and three cable
networks (CNN, MSNBC, and Lifetime) in the Southeastern United States. They found that
almost all ads provided the risk information only in the voice-over audio channel while the
video channel presented information irrelevant to the risk information (97.8%). Only 2.2%
included the risk information in both the audio channel in the voice-over and the visual
channel and in the form of superimposed text. For both 30- and 60-second ads that included
risk information, an average of 13% of commercial time was devoted to risk information.
Kaphingst and colleagues (2004) analyzed product-claim DTC television
advertisements by examining features that may interfere with customer comprehension of
risk information. They focused on product-claim advertisements broadcast during February
and March 2001 on the three major television network stations in Boston, Massachusetts.
They measured fact density, or the number of facts given about a drug’s benefits and risks,
and the type of visual information shown during the audio presentation of risk information.
They found that while ads provided an average of six facts about drug benefits and an
average of 10 facts about risks, the average number of facts-per-second was much lower for
benefits (.54 facts/sec) than for risks (.78 facts/sec.), indicating that viewers had more time to
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absorb benefits facts than risk facts. Additionally, they found that 91% of ads they studied
showed positive or neutral visual images during the presentation of risk information. Ninety-
six percent gave text references to at least one source of product information (for example, a
print ad) during the audio presentation of risk information. None showed text messages
containing risk information while the risk information was being presented in audio form.
The type of information conveyed through on-screen text included print ad reference, website
address, toll-free number, and variations in effectiveness. While these studies are useful in
providing insight into the provision of risk information in television prescription drug ads,
they do not specifically address the concept of distraction that is inherent in the television
medium and has become a growing concern for regulators.
Only one content analysis to date has specifically examined distraction in DTC
advertising. A content analysis by Hoy and Andrews (2004) assessed prime-time television
advertising adherence to the Federal Trade Commission (FTC)’s “clear and conspicuous”
disclosure requirements. While this study was not specific to DTC drug ads, the study
examined commercials for any type of product that required disclosure, including drug ads.
In their definition of distraction, Hoy and Andrews incorporated the concepts of
information load and irrelevant stimulation. They defined distraction as “extraneous
nonverbal elements such as music, sound effects, and unrelated pictorial information” (2004,
p.173). They found that 99.5% of ads that included risk information in the form of
superimposed text had some form of distraction while the SUPER was on-screen. Almost all
(99.2%) had competing sounds, including music; 33.3% had scene changes, and 86.6% had
moving visuals. Of ads with audio risk information, 97.3% included distraction during the
disclosure. Thirty-seven percent had a scene change, 89.6% had moving visuals, and 95.9%
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had other sounds, including music occurring concurrently. Only 2.7% had no distracting
elements during the audio presentation of risk information. In addition to specifically
addressing distraction during the presentation of risk disclosure, Hoy and Andrews (2004)
also measured the presentation rate of audio risk information. They found that 52.6% of ads
that contained audio risk information provided the disclosure at a rate of over 132 words per
minute and 36.6% were faster than 180 words per minute.
The Hoy and Andrews study was designed to examine adherence to the FTC’s “clear
and conspicuous” standard for risk disclosure. Similarly, Macias, Pashupati, and Lewis
(2007) and Kaphingst and colleagues (2004) examined the provision of risk information in
DTC television advertisements. The main limitation of interpreting findings of these studies
within the context of the FDA’s fair balance requirement is that they examined distracting
elements only during the presentation of risk information. Television is a very “deep”
medium in that it employs audio, imagery and textual components. Commercials often
employ moving visuals, music, scene changes and imagery with positive tone throughout the
message, not just during the risk segment. In order to assess distraction within the context of
fair balance, it is necessary to determine if distracting elements are not only present during
risk segment, but also more frequent than during the benefit segment of the commercial.
Research Questions
In order to examine the prevalence of distraction during the risk and benefit segments
of DTC television advertisements, this study operationalizes distraction in terms of both
audio and visual elements that contribute to information load and the relevance of visual
elements to audio information. Previous research has employed various qualities of both
message content and format in defining information load and information relevance in
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television advertisements. In this study, information load will be operationalized using the
visual and audio elements summarized in Table 1.
RQ1: What are the differences, if any, in the use of visual information load elements
between the risk and benefit segments of the advertisements in terms of:
RQ1a: presence of animation,
RQ1b: number of super-imposed words,
RQ1c: busy scenes (number of models),
RQ1d: number of scene changes, and
RQ1e: number of camera-angle changes?
RQ2: What are the differences, if any, in the use of audio information load elements
between the risk and benefit segments of the advertisements in terms of:
RQ2a: presence of music,
RQ2b: music familiarity,
RQ2c: music tempo,
RQ2d: presence of other sounds (besides music), and
RQ2e: presentation rate (words per second)?
Because a presentation rate of fewer than 180 words per minute is considered
sufficient audio information load, and thus is necessary for successful comprehension of
speech communication, the study also asks:
RQ3: What are the differences, if any, in the sufficiency of audio presentation rate
between the risk and benefit segments of the advertisements?
The relevance of visual elements to audio information is defined as the extent to
which the visual elements are a “matching representation” (Baron, Baron, & Miller, 1973, p.
310) of audio information.
RQ4: What are the differences, if any, in the relevance of background visuals to the
audio statements between the risk and benefit segments of the advertisements?
RQ5: What are the differences, if any, in the relevance of superimposed text to the
audio statements between the risk and benefit segments of the advertisements?
CHAPTER FOUR
Method
The study is a content analysis of the properties of DTC prescription drug television
ads broadcast during a constructed week in January 2010. Content analysis is a standard
method for advertising research (Kolbe & Burnett, 1991) and has been used in other research
to examine trends in prescription drug advertising. The strength of the method for evaluating
message content and characteristics is that the ads will be obtained and analyzed in their
naturally occurring forms. Although content analyses do not directly measure media effects,
they can provide an empirical starting point for generating new research about effects
(Kassarjian, 1977). Moreover, concern about the effects of message content on audience is
meaningless without knowledge about the content (Riffe, Lacy, & Fico, 2005).
Content analysis involves drawing representative samples of content, training coders
to use the category rules developed to measure or reflect differences in content, and
measuring the reliability (agreement or stability over time) of coders in applying to rules
(Riffe, Lacy, & Fico, 2005). Data are then analyzed to describe the patterns and
characteristics appropriate for addressing the specific research questions and hypotheses.
Sampling Procedure
This study employed a convenience sample of commercials recorded during a 14-day
period from January 4 – January 17, 2010. To obtain a representative probability sampling
of DTC ads across all seven days of the week and across various day parts, blocks of
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programming were recorded using a constructed week. The constructed week comprised six
day parts: morning (6-10 a.m.), morning daytime (10 a.m.-1 p.m.), afternoon daytime (1-4
p.m.), early fringe (4-8 p.m.), prime time (8-11 p.m.), and late fringe (11 p.m. – 2 a.m.).
Programs were recorded from the four major broadcast networks (ABC, CBS, NBC, and
FOX) (See Appendix A for constructed week). Broadcast networks were selected due to the
national nature of DTC advertising and the exploratory nature of this study. These stations
target a broad audience, whereas cable channels usually target a narrower demographic
group. This approach yielded a total of 160 hours of programming from the following local
network affiliates in the Raleigh, NC market: WTDV (ABC), WRAL (CBS), WNCN (NBC),
and WRAX (FOX). The sampling procedure yielded a total of 195 direct-to-consumer
product-claim advertisements for the 14-day period. Of these, 58 were unduplicated ads. As
described later, the study focused on unduplicated product claim ads.
Unit of Analysis
Given the focus of this project on product-claim television advertisements targeted
directly to consumers, advertisements were included in the sample if they (1) advertised a
prescription drug, (2) stated the brand name of the drug; and (3) gave at least one medical
indication for the drug. Each commercial was given a unique identifier and was saved as an
MPEG file on a DVD. The researcher then compared each ad manually and counted the first
instance of an ad in the “unduplicated” sample. An ad was considered unique if any format
or content varied from another ad. The unique MPEG video files were compiled onto a
DVD.
As noted by Reid, King and Kreshel (1994), the decision whether to include duplicate
ads in content analyses of advertising is based upon the research objectives. Because the
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purpose of this study is to examine the prevalence of distracting content in prescription drug
advertising as an industry practice and not to infer the frequency with which consumers
encounter messages with distracting content, duplicates will not be included in the analysis.
The sampling procedure yielded a total of 195 direct-to-consumer product-claim
advertisements for the 14-day period. Of these, 58 were unduplicated ads.
Coding Categories
The coding dimensions were derived from the literature discussed earlier about
information load and information relevance and included, but were not limited to, variables
specifically addressed in the FDA’s 1999 Guidance for Industry: Presenting Risk
Information in Prescription Drug and Medical Device Promotion. The coding sheet
(Appendix B) was derived from the template used in Macias, Pashupati, and Lewis’s analysis
of DTC ad content (2007) and Hoy and Andrews’s prior analysis of disclosures in television
advertising (2004).
The research questions ask about the audio and visual elements of the advertisements
during the presentation of risk and benefit information. Thus, the code sheet was organized
in three sections: 1) the advertisement characteristics, 2) risk disclosure profile, and 3)
product claim profile. The first part of the code sheet captured characteristics of the
commercials including broadcast date, network, day part, ad length, brand name,
pharmaceutical company, and medical condition being treated.
The second part of the code sheet, the risk disclosure profile, measured the
characteristics of the audio statement of drug risks, and the other audio and visual elements
presented concurrently during the audio statement of drug risks. Coders were instructed that
the risk disclosure profile was specific to the portion of the ad in which information about
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drug risks were presented verbally. Risk information was defined as information about side
effects, allergic reactions, or contraindications. This definition was based on the FDA’s
requirement that the brief summary include:
1. Who should not take the drug
2. When the drug should not be taken
3. Possible serious side effects of the drug and, if known, what can be done to lower the
chance of having them
4. Frequently occurring, but not necessarily serious, side effects (FDA, 2009).
The third section of the code sheet was the product claim profile. The product claim
profile was specific to the rest of the commercial in which the audio channel was dedicated to
benefit information. The FDA defines benefit information as “all claims about the advertised
drug or what it does” (2009). Based upon this definition, limitations on effectiveness were
included as part of the benefit information.
The same information load and information relevance variables included in the
disclosure profile were coded in the product claim profile.
Information load. Research question 1 asked if there are any differences in the use
of visual information load elements between the risk and benefit segments of the
advertisements. Visual information load was measured by the presence of animation,
number of super-imposed words, number of models, number of scene changes, and number
of camera-angle changes. Coders were asked to indicate if animation or text was present
(yes/no). If text was present, they coded the number of words on screen. Coders also
indicated the number of models on screen during the audio risk information and the number
of times the camera angles and scenes changes.
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Research question 2 asked if there are any differences in the use of audio information
load elements between the risk and benefit segments of the advertisements. Audio
information load was measured by the presence, tempo, and familiarity of music, the speech
presentation rate, and the presence of other sounds Coders were asked to indicate if music
was present (yes/no), if it was familiar to them (yes/no), and whether they considered the
beat to be fast, medium, or slow. They indicated the presence of other background sounds
and how many words were spoken during the risk and benefit information. To control for the
effect of duration of risk and benefit information on the number of audio and visual elements,
coders were asked to indicate the length of each commercial segment to the nearest tenth-
second. Then, the number of audio and visual information load elements per second was
calculated for each commercial segment.
To answer research question 3 about the sufficiency of speech presentation rate
during the risk and benefit segments, coders were asked to indicate the amount of time
devoted to risk and benefit information, to the nearest tenth of a second. The presentation
rate was then calculated as number of words per minute.
Relevance of visual elements to audio information. Research questions 4 and 5
pertain to the relevance of visual elements to the audio presentation of risk and benefit
information. If superimposed text was present, coders also indicated whether that text was
neutral, relevant or irrelevant to the audio information presented during the risk and benefit
segments. Text was considered to be neutral if it solely provided identifying information,
such as a Web site address, brand name or logo. For the risk segment, text was considered
relevant if it reinforced or repeated audio statements of drug risks. Irrelevant text was
defined as providing information other than drug risks, such as usage directions, product
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benefit claims, or directing viewers to another information source (e.g., “Please see our ad
in…”). For the benefit segment, text was considered to be relevant only if it reinforced or
repeated audio statements about drug benefits. Irrelevant text was defined as providing
information other than drug benefits, such as usage directions, drug risks, or directing
viewers to another information source (e.g., “Please see our ad in…”). If there were both
relevant and irrelevant text on-screen during the audio statement of risks, coders were asked
to indicate their overall impression of relevance.
Similarly, coders recorded the relevance of background visuals to the audio
statements in the risk and benefit segments of the advertisements. For the risk segment, it
was acknowledged that advertisers are not likely to show visuals of someone experiencing
side effects. However, background visuals were considered to be relevant to the audio
information if what was happening on screen “matched” the audio statements about drug
risks (for example, if the person on screen was telling the audience about drug risks).
Irrelevant visuals reinforce the benefits of taking the drug. An example would be positive
imagery of people happily “living their lives” while a voiceover talks about drug risks.
Development of coding sheet. A convenience sample of six unique DTC
commercials that aired on the NBC Evening News during November 2009 and were not part
of the sample were reviewed in the development of the coding sheet to ensure that coding
dimensions were mutually exclusive, exhaustive, and adequately captured the content. Face
validity (Riffe, Lacy, & Fico, 2009) of the coding categories was assessed by providing the
coding sheet and two sample ads to two master’s students at the Duke University who were
not official coders for the study. These students assessed their ability to complete the coding
sheet for both ads using the information provided in the training manual.
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Coding Procedure & Pilot Study
Three graduate students in journalism and mass communication at the University of
North Carolina at Chapel Hill for whom English is their native language were employed as
paid coders. Coders were provided with a training manual that described the coding
procedure and defined the content categories. The purpose of the training manual was to
ensure valid findings and to make future replications of the research possible. The researcher
facilitated an initial three-hour training session for coders. The purpose of the coder training
was to familiarize them with the content being analyzed and to establish consistent coding
procedures.
A three-step process was used to train the coders. First, the researcher reviewed the
coder training manual, warned coders against coder fatigue, and specified that they should
begin each coding session by reading the coding protocol. Second, coders practiced using
the coding protocol by coding two DTC commercials as a group. Third, coders were asked
to independently code one additional ad after the group discussion to help identify
troublesome variables and determine points of clarification to discuss before the pilot study.
To avoid sensitizing the coders to the data set, the commercials for this part of training were
ads that aired previously on the NBC Evening News and thus were not part of the sample.
An official pilot study was conducted to check inter-coder reliability and the clarity
of the coding sheet and definitions. Coders coded a convenience sample of twelve unique
DTC commercials that previously aired on the NBC Evening News and were not part of the
sample. A pretest is critical in content analysis to establish reliability. Inter-coder reliability
was assessed in the pretest using the percentage of agreement method, which measures the
degree of relevance between coders applying the same set of categories to the same content
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(Kassarjian, 1977). Each coder was given a DVD of the commercials and a stopwatch. They
were asked to enter data directly into an Excel spreadsheet on one computer while viewing
the DVD either on a television or on a second computer. Upon completion, coders sent the
Excel file to the researcher. Inter-coder reliability was calculated using the percentage
agreement method (Kassarjian, 1977).
Table 3 reports the percentage agreement for all variables in the pilot study. All but
eight variables (in boldface) achieved the acceptable 80% level as proposed by Riffe, Lacy
and Fico (1998).
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Table 3
Pilot Study Results
Variable Name Percent Agreement
Network 100.0%
Day 91.6%
Daypart 91.6%
Drug name 100.0%
Company name 91.6%
Commercial length 91.6%
Medical condition 100.0%
Risk continuity 100.0%
Risk time 83.3%
Risk words 83.3%
Risk music 100.0%
Risk music familiarity 100.0%
Risk music tempo 83.3%
Risk other sounds 91.6%
Change in tempo 91.6%
Change in volume 91.6%
Change in voiceover 91.6%
Risk text 100.0%
Risk text word count 83.3%
Risk text relevance 83.3%
Risk background visuals relevance 83.3%
Risk animation 75.0%
Risk animation speed 83.3%
Risk character count 50.0%
Risk scene changes count 41.6%
Risk camera angle changes count 41.6%
Benefit time 83.3%
Benefit word count 75.0%
Benefit music 91.6%
Benefit music familiarity 100.0%
Benefit music tempo 66.6%
Benefit other sounds 83.3%
Benefit text 100.0%
Benefit text word count 83.0%
Benefit text relevance 83.0%
Benefit background visuals relevance 83.0%
Benefit animation 66.6%
Benefit character count 50.0%
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Benefit scene changes count 50.0%
Benefit camera angle changes count 41.6%
Thus, additional training was provided for those eight variables.
Number of scene and camera angle changes. Percentage of agreement for number
of scene changes during the risk segment was only 41.6% and 50% during the product-
claims. Number of camera angle change yielded only 41.6% agreement for both risk and
benefit segments. A discussion with the coders revealed that it was often difficult to
distinguish between a moving camera angle and a scene change. Subsequently, these four
variables were condensed into two variables: number of shot changes during risk statement
and number of shot changes during product claims. A shot change was redefined in the
coding manual as a “cut” in the reel.
Number of characters on screen. The two variables number of characters on screen
during the verbal risk statement and number of characters on screen during the product-claim
segments yielded 50% and 50% agreement, respectively. This is understandable given that
many of the commercials include scenes in public places such as restaurants and parks where
there are large numbers of characters in the scene. Coders were asked to judge the number of
characters more carefully and the operational definition was reiterated. Coders were asked to
count any unique characters that they could see any part of during the segments.
Presence of animation. The two presence of animation variables yielded 78%
agreement for the risk segment and 66.6% agreement for the product-claim segment.
Follow- up discussions with coders revealed that there was disagreement about whether
moving or flashing text was considered animation. Coders were given further definition of
animation as any illustration, drawing or graphic that moves.
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Following the pilot study, the three coders then independently coded every unique ad
in the sample. To ensure independence, coders were asked not to discuss the ads with one
another, but to refer to the directions on the coding instructions for completing the data file.
Coders entered data directly into an Excel file according to directions on the code sheet.
Inter-coder reliability
Reliability scores for the 39 variables were calculated using Perreault and Leigh’s
(1989) reliability index. The reliability index (Ir) has been noted by a number of researchers
(e.g., Kolbe & Burnett, 1991; Hoy & Andrews, 2004) as the best measure for inter-judge
reliability for nominal data based on subjective judgment. The strength of the method is its
ability to account for the number of category options for a given variable when considering
chance agreement.
The overall percent agreement among the three coders was calculated for each
variable in the 58 unique ads. The overall percent agreement was then used to calculate the
reliability index (Ir). The estimated reliability indexes are included in Table 4. The reliability
indexes for all but three variables (in boldface) exceeded the critical value of .85 as suggested
by Perreault and Leigh (1989).
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Table 4
Perreault & Leigh Reliability Index
Variable Name Percent Agreement Categories Ir
Network 100.0% 4 1.00
Day 100.0% 7 1.00
Daypart 100.0% 6 1.00
Drug name 100.0% 27 1.00
Company name 97.0% 9 0.98
Commercial length 97.0% 6 0.98
Medical condition 98.0% 21 0.99
Risk continuity 93.0% 2 0.93
Risk time 86.0% 59 0.93
Risk words 88.0% 169 0.94
Risk music 100.0% 2 1.00
Risk music familiarity 100.0% 2 1.00
Risk music tempo 45.0% 3 0.42
Risk other sounds 93.0% 2 0.93
Change in tempo 86.0% 4 0.90
Change in volume 86.0% 3 0.89
Change in voiceover 95.0% 2 0.95
Risk text 100.0% 2 1.00
Risk text word count 88.0% 84 0.94
Risk text relevance 97.0% 3 0.98
Risk background visuals relevance 86.0% 3 0.89
Risk animation 88.0% 2 0.87
Risk animation speed 95.0% 3 0.96
Risk character count 95.0% 85 0.97
Risk screen changes count 95.0% 22 0.97
Benefit time 86.0% 50 0.93
Benefit word count 78.0% 133 0.88
Benefit music 98.0% 2 0.98
Benefit music familiarity 100.0% 2 1.00
Benefit music tempo 62.0% 4 0.70
Benefit other sounds 83.0% 2 0.81
Benefit text 100.0% 2 1.00
Benefit text word count 79.0% 179 0.89
Benefit text relevance 98.0% 3 0.98
Benefit background visuals relevance 83.0% 3 0.86
Benefit animation 95.0% 2 0.95
Benefit character count 78.0% 179 0.88
Benefit shot changes count 88.0% 16 0.93
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The two variables risk music tempo (Ir=.42) and benefit music tempo (Ir=.70) did not
achieve the .85 level, largely because the categories, “fast,” “medium,” or “slow” tempo are
so subjective. Similarly, the other sounds during the product claims variable only yielded Ir
= .81. These three variables were dropped from the analysis.
CHAPTER FIVE
Results
Sample Description
The sampling procedure yielded a total of 195 direct-to-consumer product-claim
advertisements for the 14-day period. Of these, 58 were unduplicated ads. For the total
sample, including duplicate ads, the largest proportion (37%) were on ABC, followed by
NBC (29%), CBS (28%), and FOX (6%). Seventeen percent of the ads were broadcast
Monday, 19% Tuesday, 21% Wednesday, 9% Thursday, 14% Friday, 8% Saturday, and 12%
Sunday. Twenty-four percent were during the early fringe day part (4-8 p.m.), followed by
21% afternoon daytime (1-4 p.m.), 20% prime time (8-11 p.m.), 17% morning (6-10 a.m.),
7% morning daytime (10 a.m.-1 p.m.), and 2% late fringe (11 p.m.-2 a.m.).
For the unduplicated sample, psychiatric and neurological disorders (such as
depression and Alzheimer’s) were the most frequently targeted conditions, accounting for 14
(24%) of the ads. Cardiovascular disease (such as high cholesterol and Peripheral Artery
Disease) was the next most frequent, with 11 (19%) of the sample. The following
conditions: respiratory conditions (6), erectile dysfunction (6), osteoporosis (3), nicotine
addiction (3), overactive bladder (3), allergies (1), contraceptive device (1), enlarged prostate
(1), and hypotrichosis (inadequate eyelashes) (1) made up the remaining 57% of the sample.
The majority (44; 75.9%) of the unique ads were 60-second ads, 3.4% (2) were 30-second
ads, 13.8% (8) were 90, and 5.2% (3) were another length.
35
Information Load
Research questions 1 and 2 operationalized distracting content as the use of visual
and audio elements that increase information load.
Visual information load elements. Research question 1 asked whether there were
differences in the presence of animation, presence of and number of superimposed words,
number of models, and number of shot changes between the risk and benefit segments of the
advertisements. As shown in Table 5, superimposed text was present in the risk (100%) and
benefit (100%) segments of all ads. Animation was present more often during benefit
information (70.7%) than during risk information (8.6%) (df = 1, p ≤ .001).
On average, there were more superimposed words during the benefit segments (M =
58.4, SD = 29.5) than the risk segments (M = 28.0, SD = 19.4) (t = -6.56, df = 98.51, p ≤
.001). Similarly, there were more shot changes during the benefit segments (M = 10.8, SD =
4.2) than the risk segments (M = 6.8, SD = 6.0) (t = -4.18, df = 102.3, p ≤ .001). However,
there was no difference in the average number of characters on screen between the risk (M =
11.2, SD = 12.9) and benefit segments (M = 11.8, SD = 10.8) (t = -0.27, df = 110.0, p = .79).
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Table 5
Visual Information Load Elements by Commercial Segment
Benefit Risk
Element N Percent N Percent  2 df p
Presence of superimposed
text
58 100.0 58 100.0 undefined 1 ≤ .001
Presence of Animation 41 70.7 5 8.6 46.69 1 ≤ .001
Benefit Risk
 SD   SD t df p
Number of superimposed
words
58.4 29.5 28.0 19.4 -6.56 98.5 ≤ .001
Number of characters 11.8 10.8 11.2 12.9 -0.27 110.0 NS
Number of shot changes 10.8 4.2 6.8 6.0 -4.18 102.3 ≤ .001
Audio information load elements. Research question 2 asked whether there were
differences in the presence of music, music familiarity, presence of other sounds besides
music, and presentation rate between the risk and benefit segments of the advertisements.
As shown in Table 6 music was present in the risk (98.3%) and benefit (98.3%) segments of
all but one ad. Music was familiar in only one ad in both the risk (1.7%) and benefit
segments (1.7%). Sounds other than music were present more often during benefit
information (25.9%) than risk information (3.4%) (df = 1, p = .002).
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Table 6
Audio Information Load Elements by Commercial Segment
Benefit Risk
Element N Percent N Percent  2 df p
Presence of music 57 98.3 57 98.3 undefined 1 NS
Familiar Music 1 1.7 1 1.7 undefined 1 NS
Presence of other sounds 15 25.9 2 3.4 9.925 1 ≤ .01
Average information load per second. As shown in Table 7, more total commercial
time (in seconds) was devoted to benefit information (M = 39.1, SD = 14.1) than to risk
information (M = 26.5, SD = 12.6) (t= -5.06, df = 112.6, p ≤ .001). There were more words
spoken per second during risk information (M = 3.4, SD = 0.3) than during benefit
information (M = 2.6, SD = 0.4) (t= 13.19, df = 102.8, p ≤ .001). There were more
superimposed words on-screen per second during benefit segments (M = 1.5, SD = 0.7) than
the risk segments (M = 1.1, SD = 0.6) (t= -3.75, df = 111.3, p ≤ .01). Shot changes were also
more frequent during the benefits (M = 0.3, SD = 0.1) than risks (M = 0.22, SD = 0.1) (t= -
2.41, df = 113.17, p = .017). There was no significant difference in the number of characters
on screen per second between the benefit and risk segments.
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Table 7
Information Load Elements by Commercial Segment
Benefit Risk
Element  SD   SD t df p
Total commercial time
(sec)
39.1 14.1 26.5 12.6 -5.06 112.6 ≤ .001
Spoken words/sec 2.6 0.4 3.4 0.3 13.19 102.8 ≤ .001
Superimposed words/sec 1.5 0.7 1.1 0.6 -3.75 111.3 ≤.001
Shot changes/sec 0.3 0.1 0.2 0.1 -2.41 113.2 ≤ .05
Characters/sec 0.3 0.3 0.5 0.8 1.66 69.9 NS
Sufficiency of Audio Presentation Rate. Research question 3 asked if there was a
difference in the sufficiency of audio presentation rate between the risk and benefit segments
of the advertisements. As demonstrated in table 8, the audio risk information (98.3%) was
presented at a rate over 180 wpm in all but one of the ads. In contrast, the benefit information
was presented at a sufficient rate of 180 or fewer wpm in nearly all (93.1%) of the ads (2 =
93.49, df = 1, p ≤ .001).
Table 8
Sufficiency of Audio Presentation Rate by Commercial Segment
Benefit Risk
N Percent N Percent
≤ 180 wpm 54 93.1 1 1.7
> 180 wpm 4 6.9 57 98.3

2 = 93.49, df = 1, p ≤ .001
Relevance of visual elements to audio information
Research questions 4 and 5 pertain to the relevance of visual elements to the audio
presentation of risk and benefit information. Research question 4 asked whether there were
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differences in the relevance of background visuals to the audio information provided during
the risk and benefit segments of the ads. As shown in Table 9, background visuals were
irrelevant more often during audio risk information (82.8%) than during audio benefit
information (0.0%) (2 = 78.51, df = 5, p ≤ .001).
Research question 5 asked whether there were differences in the relevance of
superimposed text to the audio information provided during the risk and benefit segments of
the ads. Similar to the background visuals, superimposed text was irrelevant more often
during audio risk information (74.1%) than during audio benefit information (60.3%) (2 =
124, df = 5, p ≤ .001).
Table 9
Relevance of Visual Elements to Audio Information by Commercial Segment
Visual Element Benefit Risk
N Percent N Percent
Background
Visuals
Relevant 58 100.0 10 17.2
Irrelevant 0 0 48 82.8

2 = 78.51, df = 1, p ≤ .001
Superimposed Text
Relevant 20 34.5 12 20.7
Irrelevant 35 60.3 43 74.1
Neutral 3 5.2 2 3.4

2 = 124, df = 5, p ≤ .01
CHAPTER SIX:
Discussion
The purpose of this study was to advance knowledge about distracting content in
DTC prescription drug advertising, first by providing an operational definition of distraction
in television advertisements, and then by assessing the prevalence of distracting elements in
prescription drug advertisements on televisions. To provide a definition of distraction in
television advertising, the study drew from the capacity model of attention and the related
conceptual frameworks of information load and information relevance. Guided by this
definition, the study then analyzed message elements that may increase information load and
the relevance of visual elements to audio information during the risk and benefit segments of
58 product-claim DTC television advertisements. Overall, the content analysis revealed
mixed findings about the use of distraction during benefit and risk segments of DTC
advertisements, potentially adding another layer of complexity to the DTC advertising
debate. This chapter discusses the findings, the theoretical and practical implications of the
findings, and opportunities for future research.
Distracting Elements during the Risk and Benefit Information
The research questions asked whether there were differences in distracting content
between the risk and benefit segments of DTC television advertisements.
Visual information load. When examined through the lens of visual information
load, distracting elements such as superimposed text, animation, and shot changes were more
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prevalent during benefit information than risk information. This suggests that consumers
have a much greater visual information load while benefit information is presented over the
audio channel than when risk information is presented. This greater information load during
the benefit segment may reduce audience attention to and thus hamper comprehension of
benefit information. However, while message elements increase visual information load
during benefit segments, audio information load is much greater during risk segments.
Audio information load. The audio presentation rate of spoken information was
significantly faster during the presentation of risk information than benefit information.
Furthermore, the risk information in all but one advertisement was presented at a rate much
faster than considered comprehensible by the average consumer. At the same time, claims
about drug benefits were presented much slower, and almost all of the ads presented benefits
within the presentation rate necessary for successful comprehension. This suggests that
consumers have much less time to comprehend audio risk information than benefit
information are may be more likely to understand information provided about drug benefits
than about drug risks. In discussing the findings about the presentation rate of spoken
information, it is important to note that the FDA requires that the “major statement” (FDA,
1999, p.2) of the drug’s most important risks be presented over the audio channel. This may
mean that the FDA places greater importance on the audio channel as an information source
than the video channel. Future research could examine the differences, if any, in
comprehension of audio and visual risk and benefit information as well as the relative impact
of visual information load and audio information load on comprehension.
Relevance of visual elements to audio information. Although visual information
load was much greater while benefit information was being presented over the audio channel
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than when risk information was presented, the visual information was overwhelmingly more
relevant to audio benefit information than to audio risk information. Distraction in terms of
irrelevant visual stimulation was more prevalent during risk information than benefit
information. Both superimposed text and background visuals are more likely to be irrelevant
to audio risk information. This suggests that consumers may be distracted away from the
content of audio risk information and toward the irrelevant visual content that reinforces
information other than drug risks, such as usage instructions, product benefits, or other
advertisements. Therefore, while the visual information load may contribute to greater
consumer understanding of benefit information than risk information, irrelevant visual
stimulation may lead to lesser comprehension of risk information than benefit information.
Future research could extend these findings to examine the relative impact of information
load and information relevance on comprehension.
Theoretical Implications
This research is situated within the capacity model of attention (Kahneman, 1973).
Based on the capacity model of attention, the foundation of this study is that distracting, or
dividing viewers’ attention from information in an advertisement can affect how well viewers
comprehend that information. The focus of this research was not to examine how the
content of prescription drug advertising, specifically distracting content, affects consumer
comprehension of risk and benefit information. Rather, the objective was to provide insight
into the prevalence of distracting content.
The centrality model of communication content illustrates why content analysis can
be an important tool in building theory about mass communication processes and effects
(Riffe, Lacy, & Fico, 2005). Communication content is viewed as central to the
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communication process because it can be seen both as a result of contextual factors such as
individual differences or socio-political, cultural, regulatory forces as well as the cause of a
number of individual, social, or cultural effects. Accordingly, findings from this study about
the prevalence of distraction in DTC television advertisements might inform future studies
about the forces that shape the content of DTC ads and the effects of distracting content on
comprehension. Guided by the capacity model of attention, future experimental research
may examine the relationships between audio presentation rate, irrelevant visual content, and
comprehension of drug risks and benefits.
Practical Implications
Findings suggest that there are differences in the use of distraction content in risk and
benefit information in DTC television advertisements. This raises several implications for
consumers, health care providers, and health public policy makers.
Consumers. One criticism of DTC advertising is that it is more focused on
persuading than educating. The average consumer often does not have enough knowledge
about pharmaceutical products to evaluate claims made about the therapeutic effectiveness of
a drug or to assess their personal risk from information gleaned from advertising. While
consumers rely on physicians and pharmacists to prescribe and explain the appropriate
treatment, today’s active health care consumers need to know the important risks and benefits
to consider when making decisions about which drugs to talk with their doctors. Distracting
content may interfere with consumer comprehension of risk and benefit information. If they
are able to comprehend one type of information better than another, they may not obtain all
of the necessary information about the risks and benefits of the drug with which to make an
informed decision.
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Health care providers. The study also has implications for health care providers.
Health care providers are in daily contact with patients who may ask about prescription drugs
that they have seen advertised on television. It is important for health care providers to
understand that due to distracting content, patients may not fully understand the claims about
the effectiveness of a drug or information about drug risks as portrayed in advertisements.
As a result, practitioners may need supply this information during office visits. Additionally,
to the extent that health care providers rely on information in DTC advertisements, their
comprehension of risks and benefits may also be impeded due to distraction.
Regulators. This study has two important implications for the FDA. First, given the
vague definition of distraction in current industry guidance, this study provides an objective,
quantifiable way with which to define and evaluate distraction in DTC television
advertisements. One recommendation is that the FDA adopt the definition of distraction as
audio and visual information load and irrelevant visual stimulation in industry guidance,
which will help pharmaceutical advertisers comply with the fair balance requirements.
Second, a number of findings speak to the issue of fair balance in the presentation of risks
and benefits. One finding is that, on average, advertisements devoted more time to risks than
to benefits. However, consumers were given more time to absorb spoken information about
drug risks than drug benefits. If consumers are better able to understand audio risk
information than audio benefit information, fair balance might not be achieved. This
suggests that the FDA should consider the presentation rate of spoken information in addition
to visual elements when assessing distraction in advertisements. Moreover, if irrelevant
visuals in advertisements distract the audience from carefully considering the audio
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presentation of a drug’s risks, the ad will not convey an accurate net impression of the
benefits and risks of the advertised drug.
Limitations
As with any research study, limitations to the study must be considered in interpreting
the results. First, this study was an exploratory, descriptive content analysis and therefore
can make no assumptions about the effects of distracting content on the audience. Nor can
this study determine what risk or benefit information consumers take away from a television
advertisement. Although this study operationalized risk and benefit information as
information directly stated over the audio channel, a reasonable consumer may infer drug
benefits from indirect visual information.
Additionally, as with any content analysis, the findings from this study are limited to
the sample selected. In this case, the sample was drawn from broadcasts on network
television during a two-week period. Therefore, the results may not represent all prescription
drug television advertisements currently being broadcast. Furthermore, it is possible that
characteristics of ads may change over time, especially in response to cultural shifts and
regulatory changes. Future research using longitudinal studies may examine these trends.
Lastly, assumptions about the prevalence of distracting content in DTC advertising
based on the findings in this study are limited to the variables measured. Future research
may examine other variables that were not accounted for in this study but may be distracting,
including changes in volume, voiceover, or narrator within risk and benefit segments.
CHAPTER 7:
Conclusion and Future Directions
This study begins to fill a gap in the DTC advertising literature – the prevalence of
distracting content in DTC prescription drug television commercials. Consumers are
becoming more active participants in their own health care, making it increasingly important
to ensure that consumers can learn both risk and benefit information from these
advertisements. The importance of this study is underscored by the growing concern among
scholars, regulators, and the medical community about the extent to which DTC advertising
is both persuasive and educational about drug risks and benefits. Although this study
examines just one aspect of DTC ad content, distraction, it is an important step in better
understanding how well DTC television ads are meeting FDA requirements for the fair
balance of benefits and risk information. Additionally, this study defined distraction in an
objective, quantifiable way that both regulators and pharmaceutical advertisers can use in
creating and evaluating DTC ad content.
Overall, this research furthers our understanding of distracting content of direct-to-
consumer prescription drug advertising on television. Specifically, the study proposed a
definition of distraction in television advertising and revealed that some forms of distraction
are more prevalent during risk information than during claims about drug benefits. These
findings raise issues about the use of distracting content in DTC advertising and its
implications for consumer understanding of risk and benefit information.
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Immediate next steps include extending the study to include a larger population of
DTC television advertisements, rather than attempting to infer characteristics of ads from this
sample. Additionally, future experimental work may extend the findings to examine the
effects of distracting content on consumer comprehension of risk and benefit information,
attitudes toward DTC advertising and drug brands, and intention to talk to their doctors about
and advertised drug.
Also, survey research could examine consumer perceptions of DTC advertising as an
information source. Leveraging findings in this study, a future study may examine how
distracting consumers perceive prescription drug commercials to be and if there is a
relationship between that perception and attitudes toward DTC advertising.
This research also provides a foundation on which to explore the impact of regulatory
forces on advertisers’ decision-making about content of DTC ads. For example, what
influence do self-regulatory efforts have on the presentation of benefit and risk information
in DTC ads? As evidenced by the rise in the adoption of voluntary advertising principles, a
partnership exists among drug companies, medical device manufacturers, and the
Pharmaceutical Research and Manufacturers of America to present risk information in a
manner free from distraction. However, even with industry self-regulation practices, this
study demonstrates that some types of distraction are prevalent during the presentation of risk
information.
Direct-to-consumer advertising is a profitable endeavor for pharmaceutical
companies. Responsible communication of risk and benefit information is important to
ensure that a campaign will not be stopped due to a fair balance violation. Moreover,
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presenting both risks and benefits clearly and without distraction will help ensure consumer
trust, discourage stricter regulation, and foster good industry relations.
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Appendix A: Constructed Week
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Appendix B: Code Sheet and Variable Definitions
CODING INSTRUCTIONS:
DISTRACTION IN TELEVSION ADVERTISING OF PRESCRIPTION DRUGS
(February 8, 2010)
Project Overview
The purpose of this study is to examine the content of television commercials
advertising prescription drugs. Specifically, I am interested in identifying the
presence (or absence) of distracting content in the commercials, and to what extent
distraction is present during the risk disclosure versus the rest of the commercial.
The FDA requires that prescription drug ads that make claims about a product’s
medical benefits also include a “fair balance” of information about product risks. In
television commercials, this information is called the “major statement.” The major
statement of drug risks is required to be in the audio portion of the ad but can be in
the video portion as well. Recently, regulators have become increasingly concerned
that creative elements of the commercials distract audience attention away from this
important risk information so that they can’t comprehend it.
Previous research in consumer psychology and mass communication suggests that
both the amount of information as well as the relevance of visual information to
audio information can affect audience attention and comprehension.
Coding Assignment
You will each code the same commercials. These commercials aired on the four
major networks (ABC, CBS, FOX, NBC) during two weeks in January. They were
recorded on my DVR, downloaded and saved to a DVD in MPEG format. You will
need access to media playing software in order to view the video files and complete
the coding sheet.
Process
Here is an overview of the content analysis process that we will follow:
1. Coder Training
2. Pilot Study
3. Inter-coder Reliability Check for Pilot
4. Additional Training as Needed
5. Coding
6. Final Inter-Coder Reliability Check
Coding Procedure
You will each be given an Excel spreadsheet (Drug Ad Data.xls) to record your data.
1. Every commercial has been given a unique ID for its file name.
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2. Watch each commercial one time all the way through, prior to coding, in order
to identify the risk disclosure segment(s) of the commercial. Note whether
risks are presented in one continuous segment or interspersed throughout.
3. When coding, please use one row per commercial, entering data from left to
right according to the Codebook.
4. If you have questions about a variable, please flag the commercial and ask
me.
5. Continue until all variables for each commercial have been coded and the
Excel spreadsheet is complete.
6. Email the spreadsheet to me (jdharlow@email.unc.edu) once all coding has
been complete. The last day to submit data to me is Monday, February 22,
2010.
Coding Definitions
The Code Book can be organized into three sections:
1. Commercial Characteristics (A-H):
These variables are straightforward and easy to code.
Items A-D can be coded from the file name, which is the unique commercial
ID.
2. Risk Disclosure Variables (I-Z):
These variables are specific to the portion of the ad in which information
about drug risks are presented verbally. Risks may include side effects,
allergic reactions, or contraindications (“do not take if…”). Risks do not
include limitations on effectiveness.
Variables I – K measure the characteristics of the audio statement of drug
risks.
Continuity of Risk Disclosure (I): The major statement of drug risks may be
presented in one continuous segment or interspersed throughout the ad. For
this variable, you will need to choose between “continuous” or “interspersed.”
If risks are interspersed throughout the ad, please consider each
segment of risk information when coding the remainder of the risk
disclosure variables.
Amount of Time Devoted to Risks (J): Add up the total amount of commercial
time devoted to risk information to the nearest tenth of a second. If
interspersed throughout the ad, add together the length of all segments. For
disclosures that are presented concurrently, (for example, if during the audio
statement of risks, there is text on-screen about risks) only count that time
once.
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Number of Words in the Audio Disclosure (K): Please count the total number
of words in the audio risk statements.
Variables L – O measure the presence (or absence) of other audio elements
during the required audio statement of drug risks. If present, these variables
should be relatively straightforward and easy to code.
Variables P-R ask about the transition from the main promotional message of
the ad to the risk statement. Here I am interested in noticeable changes in
the audio portion of the ad when the ad begins to talk about drug risks. In
other words, is the risk statement set off by a change in tempo, volume, or
voiceover/narrator/announcer?
Variables S – U measure the presence (or absence) and characteristics of
text on screen during the required audio statement of drug risks.
Presence of text on screen (S): is simply asking if there is on-screen text
during the presentation of risk information.
Number of Words on-screen during the Audio Disclosure (T):
Please count the number of words on screen during in the audio risk
statements. If words are presented more than once, please count every time
the words are presented in a new orientation or position.
Relevance of on-screen text (U): This asks about the relevance of on-screen
text during the risk disclosure to the audio risk information being presented.
In other words, does the on-screen text reinforce the risk information,
contradict the risk information, or is it neutral?
Please indicate that text is relevant only if it repeats something said
about drug risks.
Irrelevant text may give the viewer more information, but not about
drug risks. This information may include directions about usage,
claims about product benefits, or it may direct viewers to another
information source (“Please see our ad in…”).
Please indicate that text is neutral only if it is identifying information but
does not give any information about risks or benefits of the drug. For
example, a Web site address, brand name or logo.
If there is both relevant and irrelevant text on-screen during the audio
statement of risks, please indicate your overall impression of
relevance.
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Variables V – Z measure the characteristics of background visuals during the
required audio statement of drug risks. Here, background visuals refers to
everything happening on screen (besides text).
Relevance of background visuals (V): Here I am interested in the relevance of
background visuals to the audio risk information. This is similar to the
previous question about the relevance of on-screen text. While I realize that
an advertiser is not likely to show background visuals of someone
experiencing side effects, the visuals may reinforce the risk information being
presented, reinforce the benefits of taking the drug, or it may remain neutral.
Relevant visuals reinforce the risk information being presented
verbally. Please indicate that visuals are relevant if what is happening
on screen “matches” the audio channel. (For example, if the person on
screen is telling the audience about drug risks instead of a voiceover
saying something different than what appears on screen.)
Irrelevant visuals reinforce the benefits of taking the drug. An example
would be positive imagery of people happily “living their lives” while a
voiceover talks about drug risks.
Please indicate that visuals are neutral only if it is identifying
information but does not give any information about risks or benefits of
the drug. For example, a Web site address, brand name or logo.
If there is both relevant and irrelevant imagery on-screen during the
audio statement of risks, please indicate your overall impression of
relevance.
Presence and Speed of Animation (W-X): Here I am asking about any type of
animation on screen during the verbal risk statement. Animation is defined as
an illustration, drawing or graphic that moves (for example, an animated
character or an animated demonstration). If present, these animation
variables should be relatively straightforward and easy to code.
Number of Characters (Y): Please count the total number of unique
characters (actors, animals, animated figures) on screen during the verbal
risk segment. Please count any unique character that you can see any part
of during the segment.
Number of Shot Changes (Z): Count the total number of times the shot
changes during the risk statement. A shot change is indicated by a “cut” in
the reel.
3. Product Claim Variables (AA-AM):
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These variables are specific to the rest of the commercial; all parts of the
commercial in which the audio channel is not dedicated to risk information.
Variables AA-AC measure the characteristics of the audio channel during the
product claim portion of the commercial.
Amount of Time Devoted to Product Claims (AA): Add up the total amount of
commercial time NOT devoted to risk information to the nearest tenth of a
second.
Number of Words in Product Claims (AB): Please count the number of words
spoken in the product claim segments.
Variables AC – AF measure the presence (or absence) of other audio
elements during product claims. If present, these variables should be
relatively straightforward and easy to code
Variables AG – AI measure the presence (or absence) and characteristics of
text on screen during the product claims.
Presence of text on screen (AG) is simply asking if there is on-screen text
during the product claims.
Number of Words on Screen during Product Claims (AH): Please count the
number of words on screen during the product claim segments. If words are
presented more than once, please count every time the words are presented
in a new orientation or position.
Relevance of on-screen text (AI): This asks about the relevance of on-screen
text during the product claim to the benefit information being presented. In
other words, does the on-screen text reinforce the benefit information,
contradict the benefit information, or is it neutral?
Please indicate that text is relevant only if it repeats a benefit/product
claim.
Irrelevant text may give the viewer more information, but not about
benefits of using the product. This information may include directions
about usage, information about product risks, or it may direct viewers
to another information source (“Please see our ad in…”)
Please indicate that text is neutral only if it is identifying information but
does not give any information about risks or benefits of the drug. For
example, a Web site address, brand name or logo.
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If there is both relevant and irrelevant imagery on-screen during the
product claims, please indicate your overall impression of relevance.
Variables AJ – AM measure the characteristics of background visuals during
the product claims. Here, background visuals refer to everything happening
on screen (besides text).
Relevance of background visuals (AJ): Here I am interested in the relevance
of the background visuals to the audio benefit information. This is similar to
the previous questions about relevance.
Relevant visuals reinforce the benefits of using the drug while product
claims are being presented verbally. Please indicate that visuals are
consistent if what is happening on screen “matches” the audio channel.
Irrelevant visuals reinforce the risks associated with the drug.
Please indicate that visuals are neutral only if it is identifying
information but does not give any information about risks or benefits of
the drug. For example, a Web site address, brand name or logo.
If there is both relevant and irrelevant imagery on-screen during the
audio statement of risks, please indicate your overall impression of
relevance.
Presence of Animation (AK): Here I am asking about any type of animation on
screen during the product claims. Animation is defined as an illustration,
drawing or graphic that moves (for example, an animated character or an
animated demonstration). If present, these animation variables should be
relatively straightforward and easy to code.
Number of Characters (AL): Please count the total number of unique
characters (actors, animals, animated figures) on screen during the product-
claim segments. Please count any unique character that you can see any
part of during the segments.
Number of Shot Changes (AM): Count the total number of times the shot
changes during the product-claim segments. A “shot change” is indicated by
a “cut” in the reel.
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Codebook:
Distraction in Television Advertising of Prescription Drugs
A. ID Unique name for each commercial (file name).
Ex: AMOLF-14
B. NWK Network on which ad aired. First ONE letter of file name.
Ex: AMOLF
1 ABC
2 CBS
3 FOX
4 NBC
C. DAY Day on which ad aired. Second TWO letters of file name.
Ex: AMOLF
1 Monday
2 Tuesday
3 Wednesday
4 Thursday
5 Friday
6 Saturday
7 Sunday
D. DPRT Daypart in which ad aired. Last TWO letters of file name.
Ex: AMOLF
1 Morning
2 Morning Daytime
3 Afternoon Daytime
4 Early Fringe
5 Prime Time
6 Late Fringe
E. DRGNAME Brand name
F. CONAME Name of the pharmaceutical company (if provided). Please
enter 0 if not provided.
G. LENGTH Commercial length the nearest second.
1 15
2 30
3 60
4 75
5 90
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6 Other
H. MEDCOND Medical condition being treated
I. RSKCONT Are risks presented in one continuous segment or
interspersed throughout the ad?
0 Continuous
1 Interspersed
J. RSKTIME Total amount of commercial time devoted to risk information
(to the nearest tenth of a second).
K. RSKWRD Number of words in audio disclosure
L. RSKMUS Is there music playing during the verbal statement of risks?
0 No (Skip to V.O)
1 Yes
M. RMUSFAM Do you recognize the song?
0 No
1 Yes
N. RMUSTMP How would you best describe the TEMPO of the music?
1 Fast
2 Medium
3 Slow
O. ROTHSND Are there other sounds (besides music) in the background
during the verbal statement of risks?
0 No
1 Yes
P. CNGTMP Is there a change in tempo of the background music?
0 No Music
1 Yes, it got faster.
2 Yes, it got slower.
3 No, it stayed the same.
Q. CNGVOL Is there a change in volume?
0 No
1 Yes, it got louder.
2 Yes, it got quieter.
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R. CNGVO Is there a change in voice-over or narrator?
0 No
1 Yes
S. RSKTXT Is there text on screen during the risk disclosure?
0 No (Skip to V)
1 Yes
T. RTXTWC Total number of words on screen during audio disclosure
U. RTXTCNS Relevance of on-screen text during risk disclosure
1 Relevant
2 Irrelevant
3 Neutral
V. RVISCNS Relevance of background visuals during risk disclosure
1 Relevant
2 Irrelevant
3 Neutral
W. RVISAN Is there animation on screen during the risk disclosure?
0 No (Skip to Y)
1 Yes
X. RVISANS Animation Speed
1 Faster during the risk statement than during the rest of
the ad
2 The same speed as the rest of the ad
3 Slower during the risk statement than during the rest
of the ad
Y. RVISCH Total number of unique characters on screen during risk
statement.
Z. RVISSC Total number of shot changes during risk statement.
AA. BENTIME Total amount of commercial time devoted to product claims
(to the nearest tenth of a second).
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AB. BENWRD Number of words in product claim.
AC. BENMUS Is there music playing during the product claim?
0 No (Skip to AG)
1 Yes
AD. BMUSFAM Do you recognize the song?
0 No
1 Yes
AE. BMUSTMP How would you best describe the TEMPO of the music?
1 Fast
2 Medium
3 Slow
AF. BOTHSND Are there other sounds (besides music) in the background
during the product claims?
0 No
1 Yes
AG. BENTXT Is there text on screen during the product claims?
0 No (Skip to AK)
1 Yes
AH. BTXTWC Number of words on screen during product claims.
AI. BTXTCNS Relevance of on-screen text during product claims.
1 Relevant
2 Irrelevant
3 Neutral
AJ. BVISCNS Relevance of background visuals during product claims.
1 Relevant
2 Irrelevant
3 Neutral
AK. BVISAN Is there animation on screen during product claims?
0 No
1 Yes
AL. BVISCH Total number of unique characters on screen during product
claims.
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AM. BVISSC Total number of shot changes during product claims.
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